{
    "id": 27559,
    "fullName": "NUMA1 - ALK",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NUMA1-ALK results from the fusion of NUMA1 and ALK (PMID: 29439172). NUMA1-ALK has been identified in inflammatory myofibroblastic tumor (PMID: 29439172), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 11027,
                    "pubMedId": 29439172,
                    "title": "Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29439172"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4926,
        "geneSymbol": "NUMA1",
        "terms": [
            "NUMA1",
            "NMP-22",
            "NUMA"
        ]
    },
    "variant": "NUMA1 - ALK",
    "createDate": "03/19/2018",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 13270,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in rapid tumor reduction in a patient with inflammatory myofibroblastic tumor harboring NUMA1-ALK fusion, but was later switched to Alecensa (alectinib) due to recurrent pneumonitis, the patient achieved near complete response at 13 months (PMID: 29439172).",
            "molecularProfile": {
                "id": 29047,
                "profileName": "NUMA1 - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11027,
                    "pubMedId": 29439172,
                    "title": "Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29439172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13269,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in rapid tumor reduction in a patient with inflammatory myofibroblastic tumor harboring NUMA1-ALK fusion, but was later switched to Alecensa (alectinib) due to recurrent pneumonitis, the patient achieved near complete response at 13 months (PMID: 29439172).",
            "molecularProfile": {
                "id": 29047,
                "profileName": "NUMA1 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11027,
                    "pubMedId": 29439172,
                    "title": "Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29439172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29047,
            "profileName": "NUMA1 - ALK",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}